ICAD - iCAD, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
6.00
-0.02 (-0.33%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close6.02
Open6.03
Bid0.61 x 800
Ask7.39 x 1000
Day's Range6.00 - 6.22
52 Week Range2.42 - 7.22
Volume254,173
Avg. Volume137,592
Market Cap104.196M
Beta (3Y Monthly)0.99
PE Ratio (TTM)N/A
EPS (TTM)-0.56
Earnings DateMay 4, 2017 - May 5, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.00
Trade prices are not sourced from all markets
  • GlobeNewswire3 days ago

    iCAD Introduces ProFound AI™ for 2D Mammography in Europe

    NASHUA, N.H. and LILLE, France, June 13, 2019 -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions,.

  • GlobeNewswire3 days ago

    iCAD Announces Pricing of Public Offering of Common Stock

    NASHUA, N.H., June 13, 2019 (GLOBE NEWSWIRE) -- iCAD, Inc. (“iCAD”) (ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, announced today the pricing of its previously announced underwritten registered public offering of 1,636,364 shares of its common stock at a price to the public of $5.50 per share, for gross proceeds of approximately $9.0 million. In addition, iCAD has granted the underwriter a 30-day option to purchase up to 245,454 additional shares of common stock to cover over-allotments, if any.

  • GlobeNewswire4 days ago

    iCAD Announces Proposed Public Offering of Common Stock

    NASHUA, N.H., June 12, 2019 -- iCAD, Inc. (“iCAD”) (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today.

  • Thomson Reuters StreetEvents14 days ago

    Edited Transcript of ICAD earnings conference call or presentation 7-May-19 12:30pm GMT

    Q1 2019 ICAD Inc Earnings Call

  • Zacks Small Cap Researchlast month

    ICAD: Therapy Buoys Q1 Sales, Benefits Operating Loss. Detection Acceleration Still Expected in 2H

    Much of the strength in Q1 revenue relates to Therapy product sales, which at just over $1.0M were at the highest level in the last 3.5 years and accounted for 27% of the topline – up from historical mid-to-high teen %s. This, along with other Detection-related catalysts including what we expect to be burgeoning interest in ICAD’s breast density offering, should push that segment to double-digit yoy growth before current year-end. Total revenue was $6.8M, compared to our $6.1M estimate, and included $4.2M (+3.9% yoy, -15.6% qoq) from Detection and $2.6M (+13.2% yoy, +29.1% qoq) from the Therapy segment.

  • Analysts Expect Breakeven For iCAD, Inc. (NASDAQ:ICAD)
    Simply Wall St.last month

    Analysts Expect Breakeven For iCAD, Inc. (NASDAQ:ICAD)

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! iCAD, Inc.'s (NASDAQ:ICAD): iCAD, Inc. provides image analysis, workflow solutions, and radiati...

  • Associated Presslast month

    Icad: 1Q Earnings Snapshot

    On a per-share basis, the Nashua, New Hampshire-based company said it had a loss of 22 cents. Losses, adjusted for non-recurring costs, were 7 cents per share. The imaging and early cancer detection company ...

  • GlobeNewswirelast month

    iCAD Reports First Quarter 2019 Financial Results

    U.S. adoption of ProFound AI™, the Company’s deep-learning cancer detection software solution for digital breast tomosynthesis, gaining traction Conference call today at 8:30.

  • GlobeNewswirelast month

    iCAD Appoints R. Scott Areglado as Chief Financial Officer

    NASHUA, N.H., May 06, 2019 (GLOBE NEWSWIRE) -- iCAD, Inc. (ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today appointed R. Scott Areglado as Chief Financial Officer.  Mr. Areglado has been serving as interim Chief Financial Officer since December 2018, and previously held the role of Corporate Controller at iCAD since May 2011. Mr. Areglado has served as interim Chief Financial Officer since December 2018.  Prior to this, he was Vice President and Corporate Controller from May 2011, and previously held the role of interim Chief Financial Officer from September 2016 to November 2016.

  • GlobeNewswire2 months ago

    iCAD to Report First Quarter 2019 Financial Results on Tuesday, May 7

    NASHUA, N.H., May 01, 2019 -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it.

  • GlobeNewswire2 months ago

    iCAD Wins Three-System Public Bid with Leading Cancer Organization in Spain, Expanding European Access to Innovative Cancer Treatments with the Xoft System

    NASHUA, N.H., April 15, 2019 (GLOBE NEWSWIRE) -- iCAD, Inc. (ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that the Catalan Institute of Oncology (ICO), a leading, multi-center cancer organization in Spain, has selected iCAD as the provider of electronic brachytherapy technology for the treatment of early-stage breast cancer and gynecological cancers. ICO will introduce iCAD’s Xoft® Axxent® Electronic Brachytherapy (eBx®) System® at three hospitals located in L'Hospitalet de Llobregat, Badalona, and Girona, Spain.

  • GlobeNewswire2 months ago

    iCAD to Highlight ProFound AI™ Solution for Digital Breast Tomosynthesis at 2019 Society of Breast Imaging Annual Symposium

    Company’s Latest, Deep-Learning, Cancer Detection Software Solution Recently Launched in U.S. NASHUA, N.H., April 04, 2019 (GLOBE NEWSWIRE) -- iCAD, Inc. (ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will present its latest artificial intelligence software solution for digital breast tomosynthesis (DBT), ProFound AI™, as well as its PowerLook Density Assessment software, in the iCAD exhibition booth #301 during the 2019 Society of Breast Imaging (SBI) Annual Symposium, the largest breast imaging conference in the world.  Hosted by the SBI and the American College of Radiology, the conference will take place April 4-7, 2019, in Hollywood, Florida. ProFound AI is a high-performance, deep-learning, cancer detection and workflow solution for DBT.

  • GuruFocus.com3 months ago

    icad Inc (ICAD) Files 10-K for the Fiscal Year Ended on December 31, 2018

    The company has cancer detection and cancer therapy segments. Warning! GuruFocus has detected 1 Warning Sign with ICAD. For the last quarter icad Inc reported a revenue of $6.95 million, compared with the revenue of $7.90 million during the same period a year ago.

  • GlobeNewswire3 months ago

    iCAD Appoints Stacey Stevens as President

    NASHUA, N.H., March 28, 2019 (GLOBE NEWSWIRE) --  iCAD, Inc. (ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that Stacey Stevens has been named President. As President, Ms. Stevens will have expanded global P&L responsibility and focus on the Company's day-to-day operations and timely execution of key business initiatives. “As we continue to build our commercial momentum with ProFound AI, strengthen our market-leading position in clinical artificial intelligence (AI) solutions, and capitalize on increasing market demand, the Board of Directors concluded that Stacey is well-positioned to drive iCAD’s continued success based on her impressive track record of strategic, commercial and increasingly operational accomplishments,” said Michael Klein, Chairman and CEO of iCAD.

  • GlobeNewswire3 months ago

    iCAD to Present Corporate Overview at the Jefferies 2019 Radiation Oncology & Energy-Based Therapeutics Summit

    NASHUA, N.H., March 26, 2019 -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that.

  • Zacks Small Cap Research3 months ago

    ICAD: ProFound AI Makes U.S. Debut, Roll-Out Accelerating. More AI Products Could Soon Follow

    The ~$600k beat to our Detection product sales estimate was partially offset by one-fewer (~$200k worth) IORT (Therapy) system sales, while Services revenue in both segments was inline with our respective estimates. ICAD is putting the proceeds from a new $7M financing (5%, 3yr unsecured convertible (@$4/share) debt) to work, with a portion going to supporting the launch and U.S. roll-out of ProFound AI.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of ICAD earnings conference call or presentation 18-Mar-19 8:30pm GMT

    Q4 2018 ICAD Inc Earnings Call

  • Associated Press3 months ago

    Icad: 4Q Earnings Snapshot

    On a per-share basis, the Nashua, New Hampshire-based company said it had a loss of 20 cents. Losses, adjusted for non-recurring costs and severance costs, came to 7 cents per share. The imaging and early ...

  • GlobeNewswire3 months ago

    iCAD Reports Fourth Quarter and Full-Year 2018 Financial Results

    Company achieved key milestone in fourth quarter with FDA clearance and subsequent U.S. commercial launch of ProFound AI™ for digital breast tomosynthesis Conference call today.

  • ACCESSWIRE3 months ago

    iCAD, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 18, 2019 / iCAD, Inc. (NASDAQ: ICAD ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on March 18, 2019 at 4:30 PM Eastern Time. ...

  • Business Wire3 months ago

    iCAD Reports Strong Momentum of ProFound AI™, its Artificial Intelligence-Based Solution for Digital Breast Tomosynthesis

    iCAD, Inc. (ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported strong adoption of its latest deep-learning, cancer detection software solution for digital breast tomosynthesis (DBT), ProFound AI™. The powerful solution built on artificial intelligence (AI) delivers critical benefits to radiologists, their facilities and patients in identifying cancer earlier. “ProFound AI for DBT is like having another radiologist right there in the reading room with you,” said Randy Hicks, M.D., MBA, radiologist, co-owner and CEO at Regional Medical Imaging.

  • GlobeNewswire3 months ago

    iCAD to Present Corporate Overview at the 31st Annual ROTH Conference

    NASHUA, N.H., March 14, 2019 -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that.

  • GlobeNewswire3 months ago

    iCAD to Report Fourth Quarter and Fiscal Year Ended December 31, 2018 Financial Results on Monday, March 18

    NASHUA, N.H., March 13, 2019 -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that.

  • GlobeNewswire4 months ago

    iCAD to Partner with Leading Breast Cancer Researchers from Karolinska Institutet to Develop Artificial Intelligence-Based Breast Cancer Risk Prediction Solution

    VIENNA, Austria, Feb. 27, 2019 (GLOBE NEWSWIRE) -- iCAD, Inc. (ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced their intent to enter into an exclusive relationship with two leading researchers at The Karolinska Institutet in Stockholm, Sweden, one of the world’s foremost medical research universities, to develop an artificial intelligence (AI)-based solution that will identify a women’s individual risk of developing breast cancer. This partnership builds on an existing research agreement whereby researchers at the Karolinska Institutet developed a breast cancer risk prediction model using information identified in mammography images provided by iCAD’s AI cancer detection and density assessment solutions.